Although metformin has been shown to activate AMPK, which subsequently inhibits mTOR activity by phosphorylating and stabilizing the tuberous sclerosis complex-2 (TCS2) tumor suppressor [29,31], it has also been suggested that metformin can directly inhibit mTOR signaling independently of AMPK activation [28,77] (Figure 2). Here, MTOR is linked to neoplasm.